Finance

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN) insider ownership is 0.10%.

Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Cynthia N. Oliver, Ph.D. to the position of Senior Vice President, Process Development Operations, effective April 8, 2014. Novavax, Inc. (NASDAQ:NVAX) dropped -4.70 percent to $3.85 Friday on volume of 8.37million shares. The intra-day range of the stock was $3.65 to $4.09. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $804.87million.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the initiation of the pivotal Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on Apr 11, 2014 reported a decrease of -1.26% to the closing price of $7.14. Its fifty two weeks range is $2.15-$23.00. The total market capitalization recorded $1.33billion. The overall volume in the last trading session was 11.92million shares. In its share capital, ARIA has 186.32million outstanding shares.

MannKind Corporation (NASDAQ:MNKD) shares continue to sink in the market awaiting FDA decision on its new product, Afrezza, which is expected to be reviewed on July 15, 2014. Afrezza has already won approval for type-1 and type-2 diabetes, there is huge optimism that the same will be achieved with the FDA. On Friday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -6.42% to close the day at $6.41. Company monthly performance is recorded as 13.45%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 8.28%.